For generations, obesity has been treated as a single condition demanding a single solution, but a Mayo Clinic study published in Gastroenterology quietly challenges that assumption. Researchers examining 483 adults identified three distinct biological subtypes of obesity, finding that roughly one in four patients — those whose intestines produce abnormally low levels of appetite-regulating hormones — lost nearly twice as much body weight on tirzepatide as their peers. The discovery does not promise a cure, but it offers something medicine has long sought in the treatment of chronic disease: a
Mayo Clinic identifies obesity subtype most responsive to GLP-1 treatment
Obesity is not one disease. It's several, each with its own biology.
Mark
So the finding is that one subtype of obesity responds twice as well to tirzepatide. But how do doctors identify which patients belong to that subtype right now?
Mimi
That's the gap the study doesn't fully close. They measured hormone levels, stomach emptying rates, and hunger patterns in the research setting. Those are measurable things. But the authors themselves say prospective studies are needed before this becomes routine clinical practice.
Luke
Right—and we should be clear about what "prospective studies" means. This was a retrospective analysis of 483 people. They looked backward at data. To actually use this in a clinic, you'd need to enroll new patients, measure their biology upfront, give them tirzepatide, and track outcomes over time. That's a different study entirely.
Mark
So a doctor today couldn't order a test and know whether their patient is in the hungry-gut subtype?
Mimi
Not in any standardized way. The researchers identified the pattern, but translating that into a clinical tool—a blood test, a questionnaire, something practical—that's still ahead.
Luke
And there's another thing worth naming: the study looked at tirzepatide specifically. We don't know if patients in the low-hormone subtype would respond equally well to other GLP-1 drugs, or whether they'd respond better or worse to entirely different obesity treatments.
Mark
So the finding is real, but narrow.
Mimi
It's real and important as a research direction. It shows that obesity isn't one disease. That's valuable. But yes, the clinical application is still being worked out.
Luke
The weight loss difference is substantial though—21.5 percent versus 11.7 percent. If you could reliably identify and match patients to the right drug, that's meaningful medicine.
Mark
And the hormone production being in the intestine, not the microbiome—does that change how people might think about treatment?
Mimi
It suggests the problem isn't bacterial imbalance, which is what a lot of microbiome research focuses on. It's the intestinal cells themselves producing less of these hormones. That's a different target for future research.
Der Puls
- GLP-1 drugs like tirzepatide are transforming obesity treatment, yet a significant portion of patients plateau while others thrive — and until now, no one could reliably predict who would fall into which group.
- Mayo Clinic researchers found that about 25% of obese patients have a 'hungry gut' phenotype: their intestines underproduce appetite-suppressing hormones, their stomachs empty faster than normal, and fullness simply does not register the way it should.
- When this low-hormone subtype took tirzepatide for six months, they lost 21.5% of their body weight on average — compared to just 11.7% in the other subtypes, a gap large enough to carry serious long-term consequences for diabetes, heart disease, and metabolic health.
- The hormone deficit was traced to reduced intestinal production rather than gut microbiome differences, pointing researchers toward a specific biological pathway that could anchor future therapies and diagnostic tools.
- Prospective clinical trials are still needed before this subtyping approach enters routine practice, but the findings reframe obesity medicine: a blood test or symptom profile may one day tell a doctor which drug a patient's body will actually answer.
For generations, obesity has been treated as a single condition demanding a single solution, but a Mayo Clinic study published in Gastroenterology quietly challenges that assumption. Researchers examining 483 adults identified three distinct biological subtypes of obesity, finding that roughly one in four patients — those whose intestines produce abnormally low levels of appetite-regulating hormones — lost nearly twice as much body weight on tirzepatide as their peers. The discovery does not promise a cure, but it offers something medicine has long sought in the treatment of chronic disease: a reason why the same remedy works differently in different bodies, and a path toward matching treatment to the person rather than the diagnosis.
Not everyone loses weight the same way on GLP-1 drugs. Some patients shed pounds steadily and substantially. Others plateau. A Mayo Clinic research team set out to understand why.
The study, published in Gastroenterology, examined 483 adults with obesity and identified three distinct biological subtypes of the disease. Roughly one in four patients belonged to a group producing abnormally low levels of natural appetite-suppressing hormones — including GLP-1 itself. These individuals also emptied food from their stomachs faster than average and reported persistent hunger even after eating. Researchers called this the 'hungry gut' obesity phenotype, a condition where the normal sensation of fullness simply does not last.
When these patients took tirzepatide — a medication that mimics two hormones involved in appetite control and blood sugar regulation — the results diverged sharply. After six months, the low-hormone subtype lost an average of 21.5 percent of their body weight, compared to 11.7 percent in the other groups. The difference was not marginal. It suggested that identifying a patient's biological category before starting treatment could fundamentally change outcomes.
Dr. Andres Acosta, a gastroenterologist and obesity researcher at Mayo Clinic, framed the finding as a step toward precision medicine. 'Our findings suggest we can begin identifying which patients are most likely to respond to specific therapies rather than treating obesity as a single disease,' he said. Notably, the hormone deficit was traced to reduced intestinal production — not gut microbiome differences — pointing toward a specific biological pathway for future investigation.
The stakes extend well beyond weight loss numbers. Obesity drives type 2 diabetes, cardiovascular disease, and numerous other chronic conditions, and a patient who loses 21.5 percent of body weight rather than 11.7 percent enters subsequent years with a meaningfully different metabolic foundation. Prospective trials are still needed before this approach moves into clinical practice, but the research points toward a future where a blood test or symptom assessment — not trial and error — reveals which medication a patient's body will actually respond to.
Not everyone loses weight the same way on GLP-1 drugs. Some patients shed pounds steadily and substantially. Others plateau. A Mayo Clinic research team set out to understand why, and what they found could reshape how doctors prescribe these increasingly popular medications.
The study, published in Gastroenterology, examined 483 adults with obesity and identified three distinct biological subtypes of the disease. What emerged was striking: roughly one in four of these patients belonged to a group producing abnormally low levels of natural appetite-suppressing hormones—including GLP-1 itself. These individuals also emptied food from their stomachs faster than average and reported persistent hunger even after eating. Researchers termed this the "hungry gut" obesity phenotype, a condition where the normal sensation of fullness simply does not last.
When these patients took tirzepatide, a medication that mimics two hormones involved in appetite control and blood sugar regulation, the results diverged sharply from the rest of the group. After six months of treatment, patients in the low-hormone subtype lost an average of 21.5 percent of their body weight. Patients in the other two obesity subtypes lost 11.7 percent—nearly half as much. The difference was not marginal. It suggested that identifying which patients belonged to which biological category before starting treatment could fundamentally change outcomes.
Dr. Andres Acosta, a gastroenterologist and obesity researcher at Mayo Clinic in Minnesota, framed the finding as a move toward precision medicine. "Obesity is a complex disease driven by different biological mechanisms," he said. "Our findings suggest we can begin identifying which patients are most likely to respond to specific therapies rather than treating obesity as a single disease." The implication was clear: one medication does not fit all bodies, and matching treatment to biology matters.
The researchers also pinpointed where the hormone deficit originated. The reduced levels of appetite-regulating hormones stemmed from decreased production in the intestine itself, not from differences in gut microbiome composition. This distinction mattered because it pointed to a specific biological pathway that might be targeted or better understood in future work.
The stakes of this research extend beyond weight loss. Obesity drives the development of type 2 diabetes, cardiovascular disease, certain cancers, and numerous other serious chronic conditions. If doctors could identify the right therapy sooner—matching a patient's biological subtype to the medication most likely to work for them—the long-term health consequences could be substantial. A patient who loses 21.5 percent of body weight rather than 11.7 percent over six months enters the following years with a different metabolic foundation.
Still, the researchers were careful about the limits of their work. Prospective studies—trials designed to follow patients forward in time rather than analyzing existing data—would be necessary before this approach could move into routine clinical practice. The findings represent a proof of concept, not yet a clinical protocol. But they point toward a future in which obesity treatment is no longer a guessing game, where a blood test or symptom assessment might reveal which medication a patient's body will actually respond to.
Bemerkenswerte Zitate
Obesity is a complex disease driven by different biological mechanisms. Our findings suggest we can begin identifying which patients are most likely to respond to specific therapies rather than treating obesity as a single disease.— Dr. Andres Acosta, gastroenterologist and obesity researcher at Mayo Clinic
Möchten Sie die ganze Geschichte?
Das Original lesen bei Medical Xpress ↗
Health & Medicine